Alkermes, Inc.

Agency issues approvable letter for Vivitrol for treatment of alcohol dependence

Published in Food and Drug Law Weekly, January 27th, 2006

Alkermes, Inc., (ALKS) and Cephalon, Inc., (CEPH) announced that the U.S. Food & Drug Administration (FDA) issued an approvable letter for Vivitrol (naltrexone for extended-release injectable suspension), which is under review for the treatment of alcohol dependence in combination with a treatment program that includes psychosocial support.

The new drug application (NDA) for Vivitrol, formerly known as Vivitrex, was submitted on March 31, 2005. Alkermes and Cephalon continue to prepare for the launch of Vivitrol during the second quarter of 2006.

FDA approval of Vivitrol is contingent upon finalizing the product label and satisfying a request by the...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Food and Drug Law Weekly

Source: Food and Drug Law Weekly (2006-01-27)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry